Alessandro Armuzzi © Alessandro Armuzzi

Dear colleagues and friends of the IBD Community,

Warm greetings from the ECCO News Team as we start a new year full of hopes and dreams.

Although the pandemic and the measures to combat it have profoundly affected and are still shaping all our lives in a variety of ways, we at ECCO have adapted to recent events and are now trying to return, as far as possible, to normal. In the meantime, the whole ECCO Team has worked and continues to work hard to continue providing high-quality research, education and training opportunities with the aim of disseminating the ‘best’ standard of care for patients affected by Inflammatory Bowel Disease.

Laurent Peyrin-Biroulet © ECCO

Dear ECCO Friends,

Welcome to the last issue of ECCO News for 2022!

In ECCO News Issue 4 our Associate Editors have continued with the second episode of a new interesting series Meet the JCC Authors where Maria Chaparro and Mette Julsgaard are discussing their recent paper in the Journal of Crohn’s and Colitis titled: "Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO CONFER Multicentre Case Series [Scar Study]".

Dear ECCO friends and family,

We are delighted to announce the new series of podcast of the Journal of Crohns and Colitis (JCC)! The editorial team of ECCO News is taking over the task to bring you the best articles of JCC in a short and entertaining interview format. The authors will comment on their findings and we will discuss future directions and new areas of research in the topic and in the field of IBD.

In this first episode, we will dive into new applications of intestinal ultrasound in IBD and its potential as non-invasive method with Dr. de Voogd from Amstrerdam UMC from the article entitled: «Intestinal Ultrasound Early on in Treatment Follow-up Predicts Endoscopic Response to Anti-TNFα Treatment in Crohn’s Disease».

Welcome to our new podcast: Meet the JCC Authors !

Nuha Yassin © Nuha Yassin

Dear ECCO friends and family,

It is my pleasure to introduce the National Representatives of France at ECCO, Maeva Charkaoui & Anthony Buisson. We hope you enjoy getting to know them through this interview.

Best Wishes,

Nuha Yassin

Consultant Colorectal Surgeon

ECCO News Associate Editor

Robin Dart © ECCO

ECCO is an ever-expanding organisation with educational activities which extend throughout the year. For this ECCO News I spoke with Nicole Eichinger, the Executive Director of ECCO, to find out a bit more about her and how the ECCO Team work behind the scenes to keep this vital organisation running as smoothly as it does.

Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients

Hawthorne AB, Glatter J, Blackwell J, et al.

Aliment Pharmacol Ther. 2022;56:625–45.

Chirag Patel © Chirag Patel

Introduction

In the United Kingdom (UK), approximately 500,000 people live with IBD, and in the coming decade it is anticipated that the prevalence of IBD will surpass 1% of the population [1]. In 2019, the third UK IBD Standards for adults and children were published following extensive patient and healthcare professional consultation [2]. The IBD Standards cover seven domains: service design and delivery; pre-diagnosis referral pathways; management of the newly diagnosed patient; flare management, including self-management and timely access to specialist advice; surgery including pre- and postoperative care; inpatient medical care; and ongoing long-term treatment and monitoring in both secondary and primary care.

Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study

Jayasooriya N, Blackwell J, Saxena S, et al.

Aliment Pharmacol Ther 2022;55:1330–41.

Esha Sharma © Esha Sharma

Introduction

Inflammatory Bowel Disease (IBD) is a long-term condition of the gut which is known to impact the quality of life and social functioning of those affected due to the chronic nature of symptoms. These factors, along with communication across the gut–brain axis, cause many patients to suffer from mental health disorders such as anxiety and depression [1]. Previously, the magnitude of these comorbidities had not been established, but recent studies [1, 2] have found the prevalence to be high: a third of all patients and a half of those with an active IBD flare have been found to suffer from anxiety, while depression has been found to affect a quarter of patients and a third of those with active symptoms.

Furthermore, compared with controls, patients with IBD and mental health disorders show increased use of healthcare resources (both primary care visits and emergency secondary care visits) and increased use of antidepressant and anxiolytic medications [2]. While antidepressant medications are commonly used to treat anxiety and depression in IBD [3], understanding of how effectively these treatments are prescribed remains limited, and this is particularly true regarding the adequacy of duration of treatment in this cohort.

This population-based study was performed in the United Kingdom and used data from the primary care setting that was routinely collected electronically in general practices as part of the Clinical Practice Research Datalink (CPRD). The authors looked to review the antidepressant prescribing in primary care for those diagnosed with IBD. They focused on the rate of antidepressant treatment initiation following IBD diagnosis, the duration of antidepressant treatment according to international guidelines, potential risks of inadequate antidepressant treatment duration and general trends in antidepressant prescribing.

Patient satisfaction of propofol versus midazolam and fentanyl sedation during colonoscopy in inflammatory bowel disease

Steenholdt C, Jensen JT, Brynskov J, et al.

Clin Gastroenterol Hepatol. 2022;20:559–68.e5

Benjamin Zare © Benjamin Zare

Introduction

Many clinicians have anecdotally observed patients opting out of colonoscopies due to unpleasantness related to the procedure, and within Inflammatory Bowel Disease (IBD) populations a number of factors have been implicated in non-adherence, including logistics, health perceptions, stress and procedure problems (including discomfort) [1].

Prior studies have demonstrated patient preferences for propofol sedation over midazolam and fentanyl sedation for outpatient colonoscopy in general [2]. Furthermore, propofol has been shown to be safe, without severe adverse events or accidents [3], and nurse-administered propofol has specifically proven to be an efficient means of sedation for endoscopy in low-risk patients [4]. Nevertheless, this area has yet to be explored in the specific cohort of IBD patients.

Modern management of IBD requires the employment of ileocolonoscopy for diagnosis, as well as for the surveillance and guidance of future management. The investigators here looked to fill the aforementioned knowledge gap through design of a trial investigating the effectiveness of deep nurse-administered propofol sedation (NAPS), versus moderate midazolam and fentanyl sedation, as a means of improving patient satisfaction and future attitude towards colonoscopies.

Bram Verstockt © ECCO

Dear Y-ECCO Friends,

For very well-known pandemic reasons, we twice had to postpone the first Y-ECCO Mentorship Forum. Our third appointment with ECCO History proved to be the right one: in June 2022 we finally succeeded in completing our first Y-ECCO Mentorship Forum. Thanks to very active Y-ECCO participants and a stellar ECCO Faculty (Ailsa Hart, Peter Irving, Charlie Lees, Janneke Van der Woude and Johan Burisch), this networking and educational event was a great success. .

Charlotte Hedin © ECCO

Dear Y-ECCO Friends,

I hope you have all had time to re-charge over the summer! ECCO'23 abstract submission is currently open, with a deadline of November 21. Basic science abstracts can be considered for an Oral Presentation during the 9th Y-ECCO Basic Science Workshop, which will be held on Wednesday, March 1, 2023, between 13:05 and 15:30 CET – please tick the box if you are a Y-ECCO Member and would like to be part of this great interactive session.